会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 72. 发明申请
    • TUMOR MARKER ZSIG62
    • 肿瘤标记ZSIG62
    • WO0042183A2
    • 2000-07-20
    • PCT/US0001902
    • 2000-01-18
    • ZYMOGENETICS INC
    • SHEPPARD PAUL ONOVAK JULIA ERAYMOND FENELLA C
    • C07K14/47C12N15/12C07K14/82C07K16/32C12Q1/68G01N33/574
    • C07K14/4703
    • Studies indicate that mutations in tumor suppressor genes occur early in the process of carcinogenesis, and that these mutations are correlated with a subsequent development of cancer. The detection of such alterations would provide useful molecular markers for diagnosis, surveillance, early tumor identification and intervention, and prognosis. A novel human gene, designated as "Zsig62", resides within a region of chromosome 16q that is associated with prostate and breast cancer, and that appears to contain tumor suppressor genes. Like a tumor suppressor gene, the Zsig62 gene is expressed in particular normal tissues, but not in tumors derived from those tissues.
    • 研究表明,肿瘤抑制基因突变在致癌过程的早期发生,这些突变与随后的癌症发展相关。 这种改变的检测将为诊断,监测,早期肿瘤鉴定和干预以及预后提供有用的分子标记。 称为“Zsig62”的新型人类基因位于与前列腺和乳腺癌相关的染色体16q的区域中,并且似乎含有肿瘤抑制基因。 像肿瘤抑制基因一样,Zsig62基因在特定的正常组织中表达,但不是来源于那些组织的肿瘤。